Dubai Health Authority (DHA) added yet another international achievement to its list after the Dubai Physiotherapy and Rehabilitation Centre received a three-year accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF).
CARF awarded the accreditation after evaluating the centre and found that it met international standards and offered the latest facilities and specialised care. This recognition has contributed to high patient demand, with the centre receiving more than 4,000 patients a month.
The CARF team commended the centre’s state-of-the-art equipment and its capabilities in helping patients achieve maximum rehabilitation, allowing them to reintegrate into society. The centre’s services that contributed to achieving accreditation include robotic services that DHA started utilising to rehabilitate patients.
This technology, which rehabilitates patients who suffer from neurological disorders, paralysis or weakness in the muscles, is being used for the first time in the Middle East.
The committee also commended the centre’s other services in addition to its rehabilitation programmes.
Customer satisfaction
His Excellency Humaid Al Qatami, Chairman of the Board and Director General of DHA, said the authority was keen on providing quality services that were on a par with international standards as achieving customer satisfaction was the authority’s main priority. Al Qatami commended the centre’s staff for contributing to this achievement adding that this would not have been possible without their efforts.
He said the Dubai Physiotherapy and Rehabilitation Centre had 83 specialised medical staff and 40 therapists who offered a number of services that aim to improve patients’ quality of life.
This included specialisations such as physiotherapy, rehabilitation and physical medicine, occupational therapy, speech therapy, orthoptist fabricating devices and nutritional programmes.
The centre also provided minimally invasive procedures that involve regenerative tissue injections, including dextrose prolotherapy, platelet-rich plasma, hyaluronic acid and cellular matrix.
